The purpose of this phase 2 study is to test the efficacy of azacytidine given prior to fludarabine, cytarabine, and G-CSF for the treatment of relapsed or refractory acute myeloid leukemia.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
37
King Fahad Medical City
Riyadh, Riyadh Region, Saudi Arabia
RECRUITINGcomplete response rate
bone marrow blast \<5% with complete neutrophil (\>1000/ul) and platelets (\>100,000/ul) recovery
Time frame: 6 weeks
leukemia free survival
from time of complete remission to time of relapse or death
Time frame: 1-3 years
overall survival
from date of enrolment to date of death
Time frame: 1-3 yeears
one year leukemia free survival
probability of leukemia free survival at one year of enrolment
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.